Advertisement

Dermatomyositis

  • Matteo ZanardelliEmail author
  • Zoulikha Zarrab
  • Aldona Pietrzak
Chapter

Abstract

Dermatomyositis (DM) belongs to chronic idiopathic inflammatory myopathies (IIM), heterogeneous group of autoimmune disorders that predominately target the skeletal musculature and/or skin. Typical clinical symptoms are symmetrical proximal muscle involvement and typical cutaneous inflammatory lesions. DM affects approximately 5/1,000,000 population, twice more often in females.

Abbreviations

AICAR

5-aminoimidazole-4-carboxamide ribonucleotide

AZA

Azathioprine

CMAS

Childhood myositis assessment scale

CP

Cyclophosphamide

CsA

Ciclosporin A

DLE

Discoid lupus erythematosus

DM

Dermatomyositis

ICAM-1

Intercellular adhesion molecule-1

IIM

Idiopathic inflammatory myopathies

IL

Interleukin

IVIg

Human intravenous immunoglobulin

JDM

Juvenile dermatomyositis

MAC

Membrane attack complex of complement

MMF

Mycophenolate mofetil

MMT

Manual muscle testing

MRI

Magnetic resonance imaging

MTX

Methotrexate

PM

Polymyositis

RCTs

Randomized controlled trials

SCLE

Subacute cutaneous lupus erythematosus

SLE

Systemic lupus erythematosus

TNF

Tumor necrosis factor

VCAM

Vascular cell adhesion molecule-1

Reference

  1. Sontheimer RD, Costner MI. Dermatolmyositis. In: Wolff K, Goldsmith L, Katz S, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick’s dermatology in general medicine. 7th ed. New York: McGraw-Hill; 2008.Google Scholar

Further Reading

  1. Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol. 2012;24(6):635–41.CrossRefGoogle Scholar
  2. Alexanderson H, Lundberg IE. Disease-specific quality indicators, outcome measures and guidelines in polymyositis and dermatomyositis. Clin Exp Rheumatol. 2007;25(6 Suppl 47):153–8.PubMedGoogle Scholar
  3. Gerami P, et al. A systematic review of adult-onset clinically-amyopathic dermatomyositis: a missing link in the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54:597.CrossRefGoogle Scholar
  4. Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012;8:CD003643.Google Scholar
  5. Hundley JL, et al. Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol. 2006;54:217.CrossRefGoogle Scholar
  6. Jablonska S, Blaszczyk M. Dermatomyositis. In: Katsambas L, editor. European Handbook of Dermatological Treatments. 2nd ed. Springer 2003;126:130.Google Scholar
  7. Lam C, Vleugels RA. Management of cutaneous dermatomyositis. Dermatol Ther. 2012;25(2):112–34.CrossRefGoogle Scholar
  8. Matsubara S, Kondo K, Sugaya K, Miyamoto K. Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature. Clin Rheumatol. 2012;31(10):1493–8.CrossRefGoogle Scholar
  9. Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 2011;50(7):1344–6.CrossRefGoogle Scholar
  10. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositism. J Rheumatol. 2006;33:1021.PubMedGoogle Scholar
  11. Peloro TM, et al. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol. 2001;45:28.CrossRefGoogle Scholar
  12. Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, Brunner J, Dannecker G, Silva CA, Stanevicha V, Cate RT, van Suijlekom-Smit LW, Voygioyka O, Fischbach M, Foeldvari I, Hilario O, Modesto C, Saurenmann RK, Sauvain MJ, Scheibel I, Sommelet D, Tambic-Bukovac L, Barcellona R, Brik R, Ehl S, Jovanovic M, Rovensky J, Bagnasco F, Lovell DJ, Martini A, Paediatric Rheumatology International Trials Organisation (PRINTO), Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum. 2008;59(1):4–13.CrossRefGoogle Scholar
  13. Shinjo SK, de Souza FH, de Moraes JC. Dermatomyositis and polymyositis: from immunopathology to immunotherapy (immunobiologics). Rev Bras Reumatol. 2013;53(1):101–10.PubMedGoogle Scholar
  14. Sigurgeirsson B, et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326:363.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Matteo Zanardelli
    • 1
    Email author
  • Zoulikha Zarrab
    • 2
    • 3
  • Aldona Pietrzak
    • 4
  1. 1.Department of Neuroscience, Psychology, Drug Research and Child HealthUniversity of FlorenceFlorenceItaly
  2. 2.University of Rome “G. Marconi”RomeItaly
  3. 3.Centro Studi per la Ricerca Multidisciplinare Rigenerativa (CSRMR)RomeItaly
  4. 4.Faculty of Medicine, Department of Dermatology, Venereology and Pediatric Dermatology, Faculty of MedicineMedical University of LublinLublinPoland

Personalised recommendations